Adjuvant Strategies in Early-Stage HER2+ Breast Cancer

Video

Transcript:

Related Videos
Stephen V. Liu, MD
Samilia Obeng-Gyasi, MD, MPH,
Lauren E. Nye, MD
Emil Lou, MD, PhD, FACP
Debu Tripathy, MD
A panel of 5 experts on lung cancer
A panel of 5 experts on lung cancer
Millie Das, MD
Michael Iglesia, MD, PhD
Nan Chen, MD
Related Content
HER2+ Breast Cancer | Image Credit: © Sebastian Kaulitzki - stock.adobe.com

Real-World Study Sheds Light on Treatment Sequences and Second-Line Outcomes in HER2+ Breast Cancer

May 19th 2024
Article
OncLive On Air

Revisit the OncLive On Air Episodes From February 2024

March 18th 2024
Podcast
Carlos Barrios, MD

Ribociclib Plus NSAI Maintains Manageable Safety Profile in HR+/HER2– Early Breast Cancer

May 17th 2024
Article
Bradley J. Monk, MD, FACOG, FACS; Paolo Tarantino, MD

Monk and Tarantino Describe the Investigation of B7-H4 Vedotin–Directed ADCs in Gynecologic and Breast Cancers

January 11th 2024
Podcast
Sibylle Loibl, MD, PhD, chair, German Breast Group, chief executive officer, GBG Forschungs GmbH

Addition of Denosumab to Neoadjuvant Chemo Does Not Lead to Significant iDFS Differences in Early Breast Cancer

May 17th 2024
Article
FDA

FDA Grants Breakthrough Therapy Designation to NVL-655 for Pretreated ALK+ NSCLC

May 17th 2024
Article